Novartis Can't Duck Suit Over Cancer Drug Side Effects

By Mike Curley (June 12, 2020, 2:49 PM EDT) -- A New Mexico federal judge kept alive a patient's claims that Novartis Pharmaceuticals Corp. hid serious side effects of its blood cancer drug Tasigna, saying the patient does not need to plead the exact date he was diagnosed with those side effects at this stage of the case.

In a memorandum and order filed Thursday, U.S. District Judge James A. Parker denied Novartis' bid to dismiss Ronald Hurd's suit, as the pharmaceutical company's argument over the statute of limitation is an affirmative defense that Novartis can present, not something Hurd must anticipate in his complaint.

In the suit, Hurd alleges that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


Subscribers Only

Nature of Suit

Subscribers Only


Subscribers Only

Date Filed

Subscribers Only

Law Firms


Government Agencies

Judge Analytics

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!